FIGO/IGCS position statement: no adequately designed or powered trial shows topical treatments for high-risk HPV infection or LSIL prevent CIN3+; evidence relies on surrogates, so routine use of any current topical agent is not endorsed and surveillance remains standard.
Guideline
Pareja et al. FIGO/IGCS statement on the efficacy of topical treatments for high-risk human papillomavirus in preventing CIN 3+ lesions